Skip to content
Review Open access

Recent Advances in Various Heterocyclic Compounds as Anticancer Agents and Their Applications

Sep 2026 · International Journal of Innovative Science and Research Technology · pp. 3316 · 0 citations · 17 references

TL;DR

The role of heterocyclics in treatment of cancer including their function, mechanisms of action in cancer treatment, potential uses in medicine, their challenges for development, and potential new methods of drug delivery (such as nanoparticles) are emphasized.

Abstract

The World Health Organization (WHO) estimates that there will be approximately 22 million new cases of cancer by 2030, making it one of the leading causes of death globally. The urgent need for efficient prevention, diagnosis, and treatment methods is highlighted by this increasing incidence. Medicinal chemistry, one of the many fields involved in the search for anticancer drugs, is essential in creating compounds that minimize toxicity while specifically targeting cancer cells. Because of their structural diversity, distinctive physicochemical characteristics, and wide range of biological activity, heterocyclic compounds which are defined by ring structures containing heteroatoms like nitrogen, oxygen, or sulfur are especially valuable in this context. Heterocyclic scaffolds form the foundation of many approved anticancer drugs, interacting with important biological targets such as DNA, enzymes, and cellular receptors to modulate multiple disrupted pathways in cancer cells (e.g., cell proliferation, apoptosis, DNA replication, tumor signaling). Nitrogen, sulfur, and oxygencontaining heterocycles represent an important tool for targeting these pathways due to the ability to provide these interactions, thus contributing significantly to drug discovery. Although promising, heterocyclic compounds pose significant challenges because of their poor solubility, limited bioavailability, off-target toxicity, and drug resistance. Structure-activity relationship (SAR) studies are used to provide guidance on rational changes for improved selectivity and reductions of adverse events. Advances in nanotechnology represent new opportunities for overcoming these issues. The use of nanocarrier drug delivery systems, i.e., nanoparticles, liposomes, or polymers, has been shown to enhance solubility, circulation lifetime, and accumulation of drug at the targeted tumor through multiple mechanisms, including the enhanced permeability and retention (EPR) effect through improving pharmacokinetic and pharmacodynamic parameters. The review emphasizes the role of heterocyclics in treatment of cancer including their function, mechanisms of action in cancer treatment, potential uses in medicine, their challenges for development, and potential new methods of drug delivery (such as nanoparticles). The first-half of the review summarizes what is known from current studies and gives an example of a rational design process that has produced better efficacy; selectivity; and safety for future heterocyclic antitumor drugs.

Read PDF

Similar papers

Review Aug 2026

Pyrimidine-containing Heterocyclic Anticancer Agents: Systematic Development, SAR, and Mechanistic Pathways.

Pyrimidine-containing hybrids emerge as a privileged scaffold in medicinal chemistry for the development of effective, multitargeted anticancer agents with improved pharmacological profiles and reduced off-target effects.

Bhim Singh, Ankita Devi, V. Jaitak · 0 citations
Review Sep 2026

Phytochemical Horizons in Anticancer Drug Discovery: From Lead Molecules to Clinical Prospects

In the present day, there is a great concern about the second deadliest disease, cancer. An enormous number of mortalities rate is increasing every year because of cancer despite a few inter-cessions accessible. Advancements in potency with fewer side effects make anticancer treatment a promising area of drug devel...

M. Ramu, S. Gunturu, S. Metri et al. · 0 citations
Review Sep 2026

Purine Derivatives in Cancer Therapy: Structure-Activity Relationships and Recent Advances in Anticancer Drug Development

Cancer remains one of the most serious global health challenges, characterized by uncontrolled cellular proliferation resulting from diverse genetic, metabolic, and immunological alterations. Conventional therapies, such as chemotherapy, radiotherapy, and hormonal treatments, though widely used, are often associate...

Parminder Kaur, Shagun Aggarwal, Navneet Sharma · 0 citations
Review Open access Oct 2026

A comprehensive review on synthesis and anticancer evaluation of triazole chalcone hybrids

Cancer remains one of the leading causes of mortality worldwide, creating an ongoing need for new and potent therapeutic agents with enhanced safety and selectivity. Among various heterocyclic hybrids, triazole based chalcone derivatives have drawn attention due to their structural versatility and broad spectrum of bio...

Latha Jogi, Venkatachalam H · 0 citations
Review Open access Aug 2026

BIOACTIVE CHEMICAL NUCLEI AS PROMISING SCAFFOLDS FOR ANTICANCER DRUG DEVELOPMENT

Bioactive heterocyclic nuclei remain flexible and clinically proven platforms for the creation of novel anticancer treatments and the integration of bioactive scaffold optimization with precision oncology, computational technologies, biomarker-guided design, and novel target-modulation techniques will be necessary for...

Arun Kumar Rai, M. Rathore, Vipendra Singh et al. · 0 citations
Review Open access Sep 2026

PHYTOCHEMICALS FROM AYURVEDIC HERBS: MOLECULAR AND GENETIC BASIS OF ANTICANCER ACTIVITY — MECHANISMS, MOLECULAR TARGETS, AND THERAPEUTIC PERSPECTIVES

Key Ayurvedic phytochemicals-based nature, such as curcumin, withaferin A, nimbolide, berberine, and eugenol, are examined, detailing their mechanisms in inhibiting cancer, including apoptosis induction, cell cycle arrest, as well as tumor angiogenesis suppression.

Y. Narkhede, N. V. Borse · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.